Vnitr Lek 2023, 69(4):249-253 | DOI: 10.36290/vnl.2023.047

In the prevention of dementia, the focus should be on early and consistent treatment of hypertension

Miroslav Souček
II. interní klinika FN u sv. Anny v Brně

The brain is among the target organs of hypertension. Patients with hypertension have a higher risk of developing stroke as well as experiencing a decline in cognitive functions and dementia. Changes in the white matter and atrophy of the grey matter of the brain induced by high blood pressure develop insidiously since the onset of hypertension, even in young individuals. The effect of high blood pressure on the vessel wall cumulates in time; therefore, hypertension in younger people implies an increased risk of dementia in older age. Hypertension in young age cannot be considered a benign condition. Hypertension in middle age increases the risk of dementia by 61 %. Consistent and early hypertension control can reverse the adverse development towards dementia and lack of self-sufficiency in the patient. Data comparing individual antihypertensive drugs in terms of preventing dementia are scarce. However, renin angiotensin system blockers have been found to protect against Alzheimer's disease more than other classes of antihypertensive drugs. To achieve rapid and effective hypertension control, a combination of antihypertensive drugs is usually required. Using a fixed-dose triple combination of perindopril, indapamide, and amlodipine, blood pressure targets of < 130/80 mm Hg can be achieved within three months in 93 % of patients.

Keywords: hypertension, dementia, cognitive function, hypertension-induced end-organ damage, RAS inhibitors, ACEI, sartans, fixed-dose triple combination of antihypertensive drugs, Triplixam.

Accepted: May 31, 2023; Published: June 22, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Souček M. In the prevention of dementia, the focus should be on early and consistent treatment of hypertension. Vnitr Lek. 2023;69(4):249-253. doi: 10.36290/vnl.2023.047.
Download citation

References

  1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. Dostupné na: http://www.healthdata.org/czech­‑republic. Go to original source... Go to PubMed...
  2. Henskens LH, van Oostenbrugge RJ, Kroon AA, et al. Detection of silent cerebrovascular disease refines risk stratification of hypertensive patients. J Hypertens. 2009 Apr;27(4):846-853. Go to original source...
  3. Madsen TE, Howard G, Kleindorfer DO, et al. Sex Differences in Hypertension and Stroke Risk in the REGARDS Study: A Longitudinal Cohort Study. Hypertension. 2019 Oct;74(4):749-755. Go to original source...
  4. Elyas S, Adingupu D, Aizawa K, et al. Cerebral small vessel disease, systemic vascular characteristics and potential therapeutic targets. Aging (Albany NY). 2021 Sep 22;13(18):22030-22039. Go to original source... Go to PubMed...
  5. Melgarejo J, Vernooij MW, Ikram MA, et al. Intracranial carotid arteriosclerosis mediates the association between blood pressure and cerebral small vessel disease: the Rotterdam Study. Prezentováno na kongresu ESC 2022 v Barceloně. Go to original source...
  6. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011 Sep;10(9):819-828. Go to original source... Go to PubMed...
  7. Sierra C, de La Sierra A, Mercader J, et al. Silent cerebral white matter lesions in middle‑aged essential hypertensive patients. J Hypertens. 2002 Mar;20(3):519-524. Go to original source... Go to PubMed...
  8. Schaare HL, Kharabian Masouleh S, et al. Association of peripheral blood pressure with gray matter volume in 19- to 40-year­‑old adults. Neurology. 2019 Feb 19;92(8):e758-e773. Go to original source... Go to PubMed...
  9. Wohlfahrt P. Cognitive impairment and the threat of dementia pandemic or the journey of hypertensive patients to self­‑care deficit. Vnitr Lek. 2022 Winter;68(8):532-536. Go to original source... Go to PubMed...
  10. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997 Mar 12;277(10):813-817. Go to original source...
  11. Wang N, Harris K, Hamet P, et al. Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes. J Am Coll Cardiol. 2022 Sep 20;80(12):1147-1155. Go to original source...
  12. Suvila K, McCabe EL, Lehtonen A, et al. Early Onset Hypertension Is Associated With Hypertensive End­‑Organ Damage Already by MidLife. Hypertension. 2019 Aug;74(2):305-312. Go to original source... Go to PubMed...
  13. Maillard P, Mitchell GF, Himali JJ, et al. Effects of Arterial Stiffness on Brain Integrity in Young Adults From the Framingham Heart Study. Stroke. 2016 Apr;47(4):1030-1036. Go to original source... Go to PubMed...
  14. Shang X, Hill E, Zhu Z, et al. The Association of Age at Diagnosis of Hypertension With Brain Structure and Incident Dementia in the UK Biobank. Hypertension. 2021 Nov;78(5):1463-1474. Go to original source... Go to PubMed...
  15. Lee CJ, Hwang J, Kang CY, et al. Protective effect of controlled blood pressure on risk of dementia in low­‑risk, grade 1 hypertension. J Hypertens. 2021 Aug 1;39(8):1662-1669. Go to original source...
  16. SPRINT MIND Investigators for the SPRINT Research Group. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA. 2019 Aug 13;322(6): 524-534. Go to original source... Go to PubMed...
  17. Ungvari Z, Toth P, Tarantini S, et al. Hypertension­‑induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol. 2021 Oct;17(10):639-654. Go to original source... Go to PubMed...
  18. Barthold D, Joyce G, Wharton W, et al. The association of multiple anti­‑hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity. PLoS One. 2018 Nov 1; 13(11):e0206705. Go to original source... Go to PubMed...
  19. Nedogoda SV, Ledyaeva AA, Chumachok EV, et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig. 2013 Aug;33(8):553-561. Go to original source...
  20. Nedogoda SV, Ledyaeva AA, Chumachok EV, et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig. 2013 Aug;33(8):553-561. Go to original source... Go to PubMed...
  21. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin­‑converting enzyme inhibitors reduce mortality in hypertension: a meta­‑analysis of randomized clinical trials of renin­‑angiotensin­‑aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012 Aug;33(16):2088-2097. Go to original source... Go to PubMed...
  22. Lv J, Perkovic V, Foote CV, et al. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2012 Dec 12;12:CD004136. Go to original source... Go to PubMed...
  23. Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of angiotensin­‑converting enzyme inhibitors or angiotensin II­‑receptor blockers for ischemic heart disease. Ann Intern Med. 2009 Dec 15;151(12):861-871. Go to original source...
  24. Lévy BI, Mourad JJ. Renin Angiotensin Blockers and Cardiac Protection: From Basis to Clinical Trials. Am J Hypertens. 2022 Apr 2;35(4):293-302. Go to original source... Go to PubMed...
  25. Logunova N, Khomitskaya Y, Karpov Y, et al. Antihypertensive effectiveness and tolerability of perindopril/indapamide/amlodipine triple single-pill combination in the treatment of patients with arterial hypertension (TRICOLOR), J Hypertens. 2021;39:e373. Go to original source...
  26. Cicero AFG, Fogacci F, Rizzoli E, et al. Long­‑Term Impact of Different Triple Combination Antihypertensive Medications on Blood Pressure Control, Metabolic Pattern and Incident Events: Data from the Brisighella Heart Study. J Clin Med. 2021 Dec 17;10(24):5921. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.